Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Select Drug Profiles
Breast Cancer
,
FDA Approvals
,
Select Drug Profiles
Kisqali, a New CDK4/CDK6 Inhibitor, Approved as First-Line Therapy for HR-Positive, HER2-Negative Advanced Breast Cancer
Read More
FDA Approvals
,
Select Drug Profiles
Zejula a New Maintenance Treatment Option for Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Read More
FDA Approvals
,
Select Drug Profiles
First FDA-Approved Test to Help Detect Several Leukemias and Lymphomas
Read More
FDA Approvals
,
Select Drug Profiles
First CAR T-Cell Therapy Unanimously Recommended by FDA Advisory Committee for Treatment of B-Cell ALL in Children and Young Adults
Read More
FDA Approvals
,
In the News
,
Select Drug Profiles
Rituximab Combination Now Approved in 3 Blood Cancers
Read More
FDA Approvals
,
Select Drug Profiles
Darzalex Combined with Pomalidomide and Dexamethasone Approved for Relapsed/Refractory Multiple Myeloma
Read More
FDA Approvals
,
Select Drug Profiles
Keytruda First Cancer Drug Approved for Any Solid Tumor Based on a Biomarker Instead of Tumor Site
Read More
FDA Approvals
,
Select Drug Profiles
Imfinzi a New PD-L1 Approved for Bladder Cancer After Platinum-Based Chemotherapy
Read More
FDA Approvals
,
Select Drug Profiles
Alunbrig, an Oral Kinase Inhibitor, Receives FDA Approval for NSCLC with ALK Mutation
Read More
FDA Approvals
,
Select Drug Profiles
Rydapt First Drug in Decades Approved by the FDA for Acute Myeloid Leukemia
Read More
4
5
6
7
8
9
10
Page 7 of 20
Results 61 - 70 of 200